VolitionRX Ltd (VNRX) Stock Score, Valuation & Financial Research
VolitionRX Ltd is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.
Quick answer for VNRX
VolitionRX Ltd currently has a Wall Street Score of 24/100. The stored market price is $0.27. Its financial score is 17/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What VolitionRX Ltd does
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
VNRX financial snapshot
- Wall Street Score:
- 24/100
- Current price:
- $0.27
- Market capitalization:
- $2.3M
- Revenue:
- $2.5M
- Net income:
- $-25.6M
- Free cash flow:
- $-19.8M
- Cash:
- $2.8M
- Total debt:
- $12.0M
- EPS:
- -3.87
- Financial score:
- 17/100
- Valuation score:
- 0/100
- Revenue score:
- 49/100
What stands out
- Reported year-over-year revenue growth is +0.4%.
- Free cash flow is $-19.8M, showing cash burn in the current stored period.
- The balance sheet shows $2.8M of cash versus $12.0M of total debt, so leverage deserves attention.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 17/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research VNRX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.